Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial

耐受性 痴呆 氨溴索 葡萄糖脑苷酶 医学 安慰剂 临床全球印象 疾病 不利影响 临床试验 麻醉 内科学 病理 替代医学
作者
Carolina R. A. Silveira,Kristy K. L. Coleman,Kathy Borron,Rommel G. Tirona,Charles Anthony Rupar,Guangyong Zou,Robert Alexander Hegele,Cheryl Lea Wellington,Sophie K. Stukas,Elizabeth C. Finger,Robert Bartha,Sarah Anne Morrow,Jennie Wells,MICHAEL J. BORRIE,Don J. Mahuran,Penny A. MacDonald,Mary E. Jenkins,Mandar Jog,George K. Dresser,Susan Helen Fox
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:82 (8): 797-797 被引量:34
标识
DOI:10.1001/jamaneurol.2025.1687
摘要

Importance: Carrying a variation in the gene for β-glucocerebrosidase is a major risk factor for Parkinson disease dementia (PDD), and raising β-glucocerebrosidase levels lowers α-synuclein in cell and animals. Ambroxol is a chaperone for β-glucocerebrosidase, which increases the levels of β-glucocerebrosidase. Objective: To examine the safety and tolerability of ambroxol in PDD, test the efficacy of ambroxol in improving or slowing the progression of cognitive deficits, and acquire pharmacological data. Design, Setting, and Participants: This was a 52-week, phase 2, double-blind, placebo-controlled, randomized clinical trial conducted from February 2015 to June 2023. The study took place at a single center and was referral based. Included were patients with PDD who were older than 50 years, had Parkinson disease for at least 1 year before cognitive impairment, had mild to moderate dementia, were taking stable medications, and had a study partner. Interventions: Ambroxol low dose (525 mg per day), high dose (1050 mg per day), or placebo. Main Outcomes and Measures: Safety and tolerability outcomes were adverse events. Primary efficacy outcomes were the Alzheimer Disease Assessment Scale-cognitive subscale, version 13 (ADAS-Cog-13) and Clinician's Global Impression of Change (CGIC). Results: A total of 75 patients were screened, and 55 were randomized. Thirty-one individuals received ambroxol, with 8 patients (mean [SD] age, 78.8 [3.4] years, all male) in the low-dose group and 22 patients (mean [SD] age, 70.7 [7.6]; 19 male [86.4%]) in the high-dose group. One patient was excluded from the high-dose group due to a diagnosis of progressive supranuclear palsy. A total of 24 patients (mean [SD] age, 72.7 [6.3] years; 19 male [79.2%]) were included in the placebo group. Participants receiving ambroxol (23 of 193 adverse events [12%]) showed more gastrointestinal adverse events than those receiving placebo (9 of 172 adverse events [5%]). Statistical analyses compared ambroxol high dose vs placebo. There was no evidence to suggest differences between groups on primary or secondary outcomes. Mean (SD) ambroxol high-dose concentrations were 7.48μM (3.17μM; 95% CI, 6.08-8.87μM) in plasma and 0.73μM (0.07μM; 95% CI, 0.64-0.81μM) in cerebrospinal fluid at the end of titration. Mean (SD) β-glucocerebrosidase levels were higher at week 26 (ambroxol, 12.45 [1.97] nmol/h/mg; 91% CI, 11.54-13.36 nmol/h/mg); placebo, 8.50 [1.96] nmol/h/mg; 91% CI, 7.65-9.34 nmol/h/mg; P = .05) in the ambroxol group compared with placebo. Conclusions and Relevance: Results of this randomized clinical trial reveal that ambroxol was safe, well-tolerated, and demonstrated target engagement. However, the effect of ambroxol on cognition was not confirmed. Trial Registration: ClinicalTrials.gov Identifier: NCT02914366.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被Nia采纳,获得10
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
zyc8368发布了新的文献求助10
2秒前
2秒前
小韩同学发布了新的文献求助10
2秒前
2秒前
充电宝的应助被QT采纳,获得10
3秒前
李婉思发布了新的文献求助10
3秒前
火星上的沅完成签到,获得积分10
3秒前
LUXURY发布了新的文献求助10
3秒前
3秒前
MYRen发布了新的文献求助10
3秒前
3秒前
3秒前
打打的应助被小确幸采纳,获得10
4秒前
4秒前
韶华发布了新的文献求助10
4秒前
4秒前
川页发布了新的文献求助10
5秒前
自然诗珊完成签到,获得积分10
5秒前
邱乐乐发布了新的文献求助10
6秒前
1111的应助被asdfqwer采纳,获得50
6秒前
慕慕君卿发布了新的文献求助10
6秒前
6秒前
好好好发布了新的文献求助10
7秒前
JamesPei的应助被初景采纳,获得10
7秒前
王哪跑12发布了新的文献求助10
7秒前
dudu关注了科研通微信公众号
7秒前
仁爱问芙完成签到,获得积分10
7秒前
HY发布了新的文献求助20
7秒前
王梦奇发布了新的文献求助10
7秒前
陕西小兵发布了新的文献求助10
7秒前
孑孑发布了新的文献求助10
7秒前
MM完成签到,获得积分10
8秒前
科研通AI6.3的应助被Code_king采纳,获得10
8秒前
天天向上的应助被Code_king采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176932
求助须知:如何正确求助?哪些是违规求助? 9568078
关于积分的说明 21796533
捐赠科研通 7771599
什么是DOI,文献DOI怎么找? 3432210
关于科研通互助平台的介绍 2556478
邀请新用户注册赠送积分活动 2477762